argenX’s Vyvgart holds potential to break into ocular myasthenia gravis market, says GlobalData

argenX recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered by prefilled syringe in adult patients with ocular MG (MGFA Class I) who are acetylcholine receptor antibody–positive (AChR+). The results demonstrate Vyvgart’s potential for early disease control, says GlobalData, a leading intelligence and productivity platform.

The Vyvgart trial met its primary endpoint, which was a change from baseline in Myasthenia Gravis Impairment Index (MGII) (patient-reported outcome [PRO] subcomponent). Patients treated with Vyvgart also saw a reduction of key ocular symptoms—diplopia (double vision) and ptosis (drooping of the upper eyelids).

Jos Opdenakker, Neurology Analyst at GlobalData, comments: “The results of the trial are exciting. Given that MG is a chronic, progressive condition and that patients living with this condition experience a significant disease burden, therapies that can demonstrate early disease control are highly sought after.”

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients presenting with ocular MG. Such patients often rely upon symptomatic therapy, including acetylcholinesterase inhibitors and chronic steroids, and treatments that target underlying pathological mechanisms, such as Vyvgart, are withheld until the patient’s condition worsens. This creates significant disease burden for MG patients.

Opdenakker continues: “The results of the trial are a welcome development for AChR+ ocular MG patients, as they indicate that an exciting new treatment option may be on the horizon.”

Key opinion leaders (KOLs) previously interviewed by GlobalData have noted that there is a significant unmet need for effective treatments for patients with ocular MG. These patients are often controlled through symptomatic treatments, and although effective in non-refractory MG patients, refractory MG patients are left with few additional treatment options, and are therefore vulnerable to progression to generalized MG.

Opdenakker concludes: “The Adapt Oculus trial findings underscore the role of Vyvgart as a transformative treatment for MG. They highlight its ability to address critical unmet needs in the MG treatment landscape, this time for patients with AChR+ ocular MG. With a proven safety and efficacy profile, Vyvgart continues to display its credentials as a gold standard, disease-modifying treatment in the MG therapeutic landscape. The trial results pave the way for broader disease management and better patient outcomes in MG.”